We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,243

Sidley Austin LLP global pricing newsletter - volume three 2014
  • Sidley Austin LLP
  • Brazil, Canada, China, European Union, France, Germany, India, United Kingdom, USA
  • April 15 2014

On October 21, 2013, Brazil’s National Agency of Supplemental Health enacted Normative Resolution 388, which mandated that all private healthcare


Stricter legislation on corruption in healthcare looming
  • Squire Patton Boggs
  • Germany
  • March 22 2013

For years there has been a public debate in Germany about corruption in the healthcare sector - not least because of the huge economical detriments


Europese Commissie keurt Duitse steun voor innovatieve medische diensten goed
  • CMS Belgium
  • European Union, Germany
  • December 18 2013

Het platform zal toelaten om medische diensten te verlenen van op afstand wanneer het onmogelijk is voor de dokters en de patiënten om elkaar te


EU & Competition Law Review 10 November 2016
  • Roschier
  • European Union, France, Germany
  • November 10 2016

On 7 November 2016, the European Ombudsman ("Ombudsman") published a decision finding no maladministration by the Commission in its handling of a


Not all Bolar exemptions are the same - an update
  • Taylor Wessing
  • European Union, Germany, United Kingdom
  • September 26 2014

The 'regulatory review' defence, better known as the 'Bolar exemption' after a similar provision in US law, first came into force in October 2005


Pricing for new innovative drugs public payers attempt new approach
  • McDermott Will & Emery
  • Germany
  • June 18 2014

In 2011 an additional benefit assessment for innovative drugs and consecutive price negotiations known as the AMNOG procedure entered into force


Privacy & cybersecurity update, issue 3 - October, 2014
  • Jones Day
  • Australia, Netherlands, New Zealand, Russia, Taiwan, USA, Germany, Hong Kong, Ireland, Italy, Japan, Mexico, Brazil, Canada, Chile, China, European Union, France
  • October 15 2014

On August 1, the Federal Trade Commission ("FTC") issued a report on mobile shopping applications. In it, the FTC found that such apps often fail to


Privacy Commissioner criticizes draft law on e-health
  • Squire Patton Boggs
  • Germany
  • February 9 2015

The Privacy Commissioner of Schleswig-Holstein recently criticized the draft law on e-health, published by the Federal Ministry of Health, for


German FSA releases new Transparency Code
  • Eversheds Sutherland (International) LLP
  • Germany
  • August 22 2014

German Association FSA "Voluntary Self-regulation for the pharmaceutical industry" ("Freiwillige Selbstkontrolle für die Arzneimittelindustrie"


German Federal Supreme Court on whether therapy-related instructions may contribute to patentability in case of a claim directed to a substance for use in therapeutic treatment (decisions of February 25, 2014 Cases X ZB 513 and X ZB 613 Collagenase
  • BARDEHLE PAGENBERG Partnerschaft mbB
  • Germany
  • July 14 2014

Therapy-related instructions ("therapiebezogene Anweisungen") may contribute to patentability if they objectively aim at allowing, enhancing